Low vitamin D levels linked to more severe multiple sclerosis symptoms

October 2, 2012

Low blood levels of vitamin D are associated with an increased number of brain lesions and signs of a more active disease state in people with multiple sclerosis (MS), a new study finds, suggesting a potential link between intake of the vitamin and the risk of longer-term disability from the autoimmune disorder.

But researchers, led by Ellen M. Mowry, M.D., M.C.R., an assistant professor of neurology at the Johns Hopkins University School of Medicine and principal investigator of a multicenter clinical trial of D supplementation in patients, caution that more research is needed to determine if large doses of vitamin D help without harming MS patients.

Mowry's study, conducted mostly when she worked at the University of California, San Francisco, shows a strong correlation between vitamin D levels in the body (measured through ) and the characteristic of MS as measured with . Results were described in the August issue of .

"Even though lower levels of vitamin D are associated with more inflammation and lesions in the brain, there is no evidence that taking vitamin D supplements will prevent those symptoms," she says "If we are able to prove that through our currently-enrolling trial, it will change the way people with are treated."

In people with MS, the body's immune system attacks the coating of in the brain and spinal cord. The coating, made of a fatty protein called myelin, insulates the nerves and helps them send that control movement, speech and other functions. When myelin is attacked, inflammation interferes with message transmission, activity that shows up on an MRI as lesions, which look like white spots.

In the most common form of MS, called relapsing-remitting MS, patients may at times have no symptoms, but at other times may suffer from "attacks" (or "") of symptoms such as blurred vision, numbness and weakness. There is currently no cure for the disease but there are medications to help reduce the number of attacks and to help reduce symptoms left over if a person hasn't fully recovered from an attack.

For the study, Mowry and her colleagues used data from a five-year study of 469 people with MS. Each year, beginning in 2004, researchers drew blood from, and performed MRIs on, the brains of study participants, looking for both new lesions and active spots of disease, which lit up when a contrast dye was used. The investigators found that each 10-nanograms-per-milliliter increase in vitamin D levels was associated with a 15 percent lower risk of new lesions and a 32 percent lower risk of spots of active disease, which require treatment with medication to reduce likelihood of permanent nerve damage. Higher vitamin D levels were also associated with lower subsequent disability.

The impact of vitamin D levels remained even after other factors that can affect disease progress were accounted for, including smoking status, current MS treatment, age and gender.

At least early in MS, the more new lesions and active spots of disease, the more likely a patient is to develop longer-term disability, Mowry says. Some people with relapsing-remitting MS progress to a more serious form due to damage of the underlying nerve cells.

From one year to the next, Mowry says, she and her colleagues were able to predict the appearance of new lesions and active disease spots based on vitamin D levels from the year before. Active and new lesions indicate that a patient's MS is not under optimal control.

Previous studies have indicated that lower vitamin D levels are associated with increased relapse risk in certain . Those studies relied on patients to report their attacks, which is sometimes a less reliable assessment than MRI.

Some patients already take extra vitamin D because of publicity about earlier studies. However, Mowry says that there is no research proving vitamin D alleviates symptoms or suggesting what dose is best or safest. And nothing is known about whether vitamin D can prevent the autoimmune disorder, she says.

"People think vitamin D is available over the counter so it must be safe," Mowry says. "But vitamin D is a hormone, and any medication really does need to be thoroughly tested before we definitely recommend it. That's the main reason why we are now performing a randomized trial of vitamin D supplementation. People with MS should talk with their doctors about the pros and cons of taking before starting the supplement."

Explore further: High-dose vitamin D may not be better than low-dose vitamin D in treating MS

Related Stories

High-dose vitamin D may not be better than low-dose vitamin D in treating MS

October 24, 2011
Low vitamin D levels are associated with an increased risk of developing multiple sclerosis (MS), but the first randomized, controlled trial using high-dose vitamin D in MS did not find any added benefit over and above ongoing ...

New link found between MS treatment and vitamin D

July 30, 2012
(Medical Xpress) -- A new study by researchers at the Menzies Research Institute Tasmania (Menzies) suggests that one of the main treatments for multiple sclerosis (MS) may also increase the amount of vitamin D patients receive ...

Low vitamin D levels may be associated with recurrent inflammatory spinal cord disease

November 14, 2011
Vitamin D levels are significantly lower in patients with recurrent inflammatory spinal cord disease, according to a study published Online First by Archives of Neurology.

Recommended for you

Can brain lesions contribute to criminal behavior?

December 18, 2017
New research published in the Proceedings of the National Academy of Sciences indicates that lesions to brain areas in individuals exhibiting criminal behavior all fall within a particular brain network involved in moral ...

Direct amygdala stimulation can enhance human memory

December 18, 2017
Direct electrical stimulation of the human amygdala, a region of the brain known to regulate memory and emotional behaviors, can enhance next-day recognition of images when applied immediately after the images are viewed, ...

How electroconvulsive therapy relieves depression per animal experiments

December 18, 2017
In a study using genetically engineered mice, Johns Hopkins researchers have uncovered some new molecular details that appear to explain how electroconvulsive therapy (ECT) rapidly relieves severe depression in mammals, presumably ...

'Simple, but powerful' model reveals mechanisms behind neuron development

December 18, 2017
All things must come to an end. This is particularly true for neurons, especially the extensions called axons that transmit electrochemical signals to other nerve cells. Without controlled termination of individual neuron ...

Restless leg syndrome risk factor for heart-related death

December 18, 2017
Restless leg syndrome (RLS) is associated with increased risk of cardiovascular disease (CVD)-related death among women, according to research published online today (Dec. 15) in the January 2018 issue of Neurology, the medical ...

Study finds graspable objects grab attention more than images of objects do

December 15, 2017
Does having the potential to act upon an object have a unique influence on behavior and brain responses to the object? That is the question Jacqueline Snow, assistant professor of psychology at the University of Nevada, Reno, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.